Sources: WHO, Our World in Data, World Bank
16 patient group respondents from Romania, informed us how they interact and engage with drug regulators to ensure equitable or more affordable access to medicines.
44% of respondents from Romania ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators.
Total number of patients reached = ~111.1K
Patients reached by each patient group (5 respondents).
interactions
Tebentafusp recently, checkpoint inhibitors and Brafi/Meki therapies in the past.
Tebentafusp recently, checkpoint inhibitors and Brafi/Meki therapies in the past.
National cancer patient group
interactions
To Ministry of Health, National Health insurance.
National neurological-conditions patient group
actions & advocacy
The federation is the watchdog for cancer patients’ access to treatment.
The federation is the watchdog for cancer patients' access to treatment.
National cancer patient group
actions & advocacy
Contacts with the National Agency for Medication for inclusion of novel treatment drugs in the Oncological program.
Contacts with the National Agency for Medication for inclusion of novel treatment drugs in the Oncological program.
National cancer patient group
The percentages below highlight how the 7 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
3 mentions
2 mentions
1 mention
actions & advocacy
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
